Loading clinical trials...
Loading clinical trials...
Single-arm, Open-label, Single-center Phase II Clinical Study of Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer
Conditions
Interventions
Oxaliplatin
Capecitabine
+1 more
Locations
1
China
Xuewei Ding
Tianjin, Tianjin Municipality, China
Start Date
August 1, 2023
Primary Completion Date
August 1, 2024
Completion Date
August 1, 2024
Last Updated
August 3, 2023
NCT06901531
NCT03739801
NCT04263870
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions